NCT06355986Not yet recruiting
Computerized Decision Support to Prevent Stroke in Atrial Fibrillation
Community-Based, Cluster-Randomized Trial of Electronic Alert-Based Computerized Decision Support to Prevent Stroke in High-Risk Ambulatory Patients With Atrial Fibrillation (AF-ALERT3)
Source: ClinicalTrials.gov · Last updated 25 Feb 2026
Brief summary (registry, in English)
Atrial fibrillation (AF) is the most preventable cause of stroke. However, despite widely available risk stratification tools, numerous options for oral anticoagulation, and evidence-based practice guidelines, anticoagulation for stroke prevention in AF is consistently under-prescribed. In a pair of observational cohort analyses within the Mass General Brigham (MGB) health system, prescription of anticoagulation for stroke prevention in AF was less frequent in ambulatory clinic patients than in those who were hospitalized at the time of assessment (46.9% vs. 57.2%). Two single academic medical center randomized controlled trials demonstrated success for increasing adherence to guideline recommendations for stroke prevention in AF. To address the feasibility and impact of a computerized decision support (CDS) strategy in the non-tertiary care, community medical center setting, this study will involve a multicenter, cluster-randomized controlled trial of a more sophisticated CDS focused not only on implementation stroke prevention but also on bleeding risk assessment and management.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 2500 (estimated)
- First submitted
- 27 Mar 2024
- Start date
- 30 Dec 2026
- Primary completion date
- 30 Jul 2027
- Lead sponsor
- Brigham and Women's Hospital
- Diseases
- Stroke, Atrial fibrillation
- NCT number
- NCT06355986
What you commit to
- Study type: Interventional
- Planned participants: 2500
- From 30 Dec 2026 to the primary completion date, 30 Jul 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Active prescription for anticoagulant therapy
Other
- CHA2DS2VASc score \< 2 for males
- CHA2DS2VASc score ≤ 2 for females
Who the study is looking for
- Male and Female
- Age ≥ 18 years
- Problem list entry of atrial fibrillation or atrial flutter
- CHA2DS2VASc score ≥ 2 for males
- CHA2DS2VASc score ≥ 3 for females
- No prescription for anticoagulant therapy
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mass General Brigham Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
| St. Elizabeth Health Coordinator of this site? Confirm its status | Edgewood | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.